- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04091139
Research of Unified Protocol for the Treatment of Common Mental Disorders in Adolescents in Hong Kong
A Randomized-controlled Trial of a Locally Adapted Unified Protocol - Transdiagnostic Cognitive Behavioural Therapy for the Treatment of Common Mental Disorders in Adolescents in Hong Kong
The Unified Protocol (UP) is an emotion-focused, cognitive-behavioural intervention that is developed to target core temperamental characteristics underlying anxiety and depressive disorders. Ehrenreich and colleagues developed UP for adolescents (UP-A). The current study aims at evaluating efficacy of UP-A for the treatment of emotional disorders in Chinese adolescents in Hong Kong.
The current study would recruit 27 Chinese-speaking patients, age 13 to 18, with a primary diagnosis of any Diagnostic and Statistical Manual (Fifth edition) anxiety disorders and/or depressive disorder. They would be randomized into one of the two treatment arms, namely UP-A treatment condition (UP-A), and treatment-as-usual (TAU) condition. Following randomization, participants in the UP-A condition would attend individual treatment based on UP-A, which last for 10 to 12 weeks. Participants in the TAU condition would be provided with usual clinical psychological service (i.e. treatment as usual) in the first 12 weeks before they start attending the same individual treatment program.
Primary outcomes would be patient's self-rated measures on clinical symptoms, and secondary outcomes would be their clinical diagnoses, parent-rated and other self-rated measures. It is hypothesized that, comparing to those in TAU, participants in the UP-A condition would show improvements in depressive symptoms, anxiety symptoms and functional impairment at the end of treatment. When the outcomes of all participants are combined, it is hypothesized that participants will show demonstrate improvement in depressive symptoms, anxiety symptoms, and functional impairment after completing the UP-A and at the 3-month follow-up.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
HK
-
Hong Kong, HK, Hong Kong, HK
- Department of Psychology, The Chinese University of Hong Kong
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age between 13 to 18 years.
- Primary diagnosis of any depression and/or anxiety disorders in fifth edition of the Diagnostic and Statistical Manual
- Use Chinese as primary written language
- For adolescents on medication, there must be 6-week stabilization period before study entry
Exclusion Criteria:
- Diagnoses of psychotic disorders, organic brain disease, bipolar disorder
- In high risk of self-harm or suicide
- Significant cognitive impairment (intellectual quotient lower than 80)
- Autism Spectrum Disorders
- Externalizing disorders with serious treatment interfering disruptive behavioural problems or substance abuse
- Attending concurrent psychotherapy
- Experience of attending a full-course of cognitive behavior therapy for anxiety or depression
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Unified protocol for adolescents (UP-A)
The Unified Protocol (UP) is an emotion-focused, cognitive-behavioural intervention that is developed to target core temperamental characteristics underlying anxiety and depressive disorders. The goal of the UP is to help patients to cultivate a greater willingness to experience uncomfortable emotions and to reduce maladaptive emotion response tendencies, so as to lessen the intensity and frequency of uncomfortable emotions. Ehrenreich and colleagues modified from the original UP and developed the UP for adolescents (UP-A). A Chinese treatment protocol would be developed based on the UP-A. Contents of the treatment includes motivational enhancement, psychoeducation of emotion, avoidance and emotion driven behaviours, interoceptive exposure, cognitive reappraisal, emotion awareness training and emotion exposure. It consists of 10 to 12 individual sessions for the adolescents, and 4 to 6 sessions for parents or guardians. |
The Unified Protocol (UP) is an emotion-focused, cognitive-behavioural intervention that is developed to target core temperamental characteristics underlying anxiety and depressive disorders. The goal of the UP is to help patients to cultivate a greater willingness to experience uncomfortable emotions and to reduce maladaptive emotion response tendencies, so as to lessen the intensity and frequency of uncomfortable emotions. Ehrenreich and colleagues modified from the original UP and developed the UP for adolescents (UP-A). A Chinese treatment protocol would be developed based on the UP-A. Contents of the treatment includes motivational enhancement, psychoeducation of emotion, avoidance and emotion driven behaviours, interoceptive exposure, cognitive reappraisal, emotion awareness training and emotion exposure. It consists of 10 to 12 individual sessions for the adolescents, and 4 to 6 sessions for parents or guardians. |
|
Active Comparator: Treatment as usual (TAU)
TAU participants will receive usual clinical psychological service provided in the clinic (i.e.
treatment as usual) in the first 12 weeks, before they start receiving same individual treatment program based on UP-A.
|
TAU participants will receive usual clinical psychological service provided in the clinic (i.e.
treatment as usual) in the first 12 weeks, before they start receiving same individual treatment program based on UP-A.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change of depressive symptoms from baseline to treatment completion and at the three-month follow-up
Time Frame: UP-A: Week 0 (pre-treatment), Week 12 (post-treatment) and Week 24 (follow-up); TAU: Week 0 (baseline), Week 12 (pre-treatment), Week 24 (post-treatment) and Week 36 (follow-up)
|
Beck Depression Inventory for Youth (BDI-Y)
|
UP-A: Week 0 (pre-treatment), Week 12 (post-treatment) and Week 24 (follow-up); TAU: Week 0 (baseline), Week 12 (pre-treatment), Week 24 (post-treatment) and Week 36 (follow-up)
|
|
Change of anxiety symptoms from baseline to treatment completion and at the three-month follow-up
Time Frame: UP-A: Week 0 (pre-treatment), Week 12 (post-treatment) and Week 24 (follow-up); TAU: Week 0 (baseline), Week 12 (pre-treatment), Week 24 (post-treatment) and Week 36 (follow-up)
|
Beck Anxiety Inventory for Youth (BAI-Y)
|
UP-A: Week 0 (pre-treatment), Week 12 (post-treatment) and Week 24 (follow-up); TAU: Week 0 (baseline), Week 12 (pre-treatment), Week 24 (post-treatment) and Week 36 (follow-up)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change of psychiatric diagnosis of common mental disorders (based on fifth edition of Diagnostic and Statistical Manual) from baseline to treatment completion
Time Frame: UP-A: Week 0 (pre-treatment) and Week 12 (post-treatment); TAU: Week 0 (baseline), Week 12 (pre-treatment) and Week 24 (post-treatment)
|
M.I.N.I. International Neuropsychiatric Interview for Children and Adolescent (MINIKID; English version 7.0.2)
|
UP-A: Week 0 (pre-treatment) and Week 12 (post-treatment); TAU: Week 0 (baseline), Week 12 (pre-treatment) and Week 24 (post-treatment)
|
|
Change of level of suicidality from baseline to treatment completion
Time Frame: UP-A: Week 0 (pre-treatment) and Week 12 (post-treatment); TAU: Week 0 (baseline), Week 12 (pre-treatment) and Week 24 (post-treatment)
|
M.I.N.I. International Neuropsychiatric Interview for Children and Adolescent (MINIKID; English version 7.0.2) - Part B "Suicidality (for ages 13 through 17)"
|
UP-A: Week 0 (pre-treatment) and Week 12 (post-treatment); TAU: Week 0 (baseline), Week 12 (pre-treatment) and Week 24 (post-treatment)
|
|
Change of functional impairment from baseline to treatment completion and at the three-month follow-up
Time Frame: UP-A: Week 0 (pre-treatment), Week 12 (post-treatment) and Week 24 (follow-up); TAU: Week 0 (baseline), Week 12 (pre-treatment), Week 24 (post-treatment) and Week 36 (follow-up)
|
Sheehan Disability Scale (SDS, 2012 version)
|
UP-A: Week 0 (pre-treatment), Week 12 (post-treatment) and Week 24 (follow-up); TAU: Week 0 (baseline), Week 12 (pre-treatment), Week 24 (post-treatment) and Week 36 (follow-up)
|
|
Change of self-reported competencies and psychopathologies from baseline to treatment completion and at the three-month follow-up
Time Frame: UP-A: Week 0 (pre-treatment), Week 12 (post-treatment) and Week 24 (follow-up); TAU: Week 0 (baseline), Week 12 (pre-treatment), Week 24 (post-treatment) and Week 36 (follow-up)
|
Youth Self-report (YSR; 1991 & 2001 combined version, Chinese edition)
|
UP-A: Week 0 (pre-treatment), Week 12 (post-treatment) and Week 24 (follow-up); TAU: Week 0 (baseline), Week 12 (pre-treatment), Week 24 (post-treatment) and Week 36 (follow-up)
|
|
Change of parental-reported competencies and psychopathologies from baseline to treatment completion and at the three-month follow-up
Time Frame: UP-A: Week 0 (pre-treatment), Week 12 (post-treatment) and Week 24 (follow-up); TAU: Week 0 (baseline), Week 12 (pre-treatment), Week 24 (post-treatment) and Week 36 (follow-up)
|
Child Behavior Checklist (CBCL; 1991 & 2001 combined version, Chinese edition)
|
UP-A: Week 0 (pre-treatment), Week 12 (post-treatment) and Week 24 (follow-up); TAU: Week 0 (baseline), Week 12 (pre-treatment), Week 24 (post-treatment) and Week 36 (follow-up)
|
|
Change of depressive symptoms throughout the treatment, from baseline to treatment completion and at the three-month follow-up
Time Frame: UP-A: Week 0 (pre-treatment), Week 1-12 (10-12 treatment sessions), Week 12 (post-treatment), Week 24 (follow-up); TAU: Week 0 (baseline), Week 12 (pre-treatment), Week 13-24 (10-12 treatment sessions), Week 24 (post-treatment), Week 36 (follow-up)
|
Patient Health Questionnaire (PHQ-9)
|
UP-A: Week 0 (pre-treatment), Week 1-12 (10-12 treatment sessions), Week 12 (post-treatment), Week 24 (follow-up); TAU: Week 0 (baseline), Week 12 (pre-treatment), Week 13-24 (10-12 treatment sessions), Week 24 (post-treatment), Week 36 (follow-up)
|
|
Change of anxiety symptoms throughout the treatment, from baseline to treatment completion and at the three-month follow-up
Time Frame: UP-A: Week 0 (pre-treatment), Week 1-12 (10-12 treatment sessions), Week 12 (post-treatment), Week 24 (follow-up); TAU: Week 0 (baseline), Week 12 (pre-treatment), Week 13-24 (10-12 treatment sessions), Week 24 (post-treatment), Week 36 (follow-up)
|
Generalized Anxiety Disorder Questionnaire (GAD-7)
|
UP-A: Week 0 (pre-treatment), Week 1-12 (10-12 treatment sessions), Week 12 (post-treatment), Week 24 (follow-up); TAU: Week 0 (baseline), Week 12 (pre-treatment), Week 13-24 (10-12 treatment sessions), Week 24 (post-treatment), Week 36 (follow-up)
|
|
Change of self-reported problem severity throughout the treatment, from baseline to treatment completion and at the three-month follow-up
Time Frame: UP-A: Week 0 (pre-treatment), Week 1-12 (10-12 treatment sessions), Week 12 (post-treatment), Week 24 (follow-up); TAU: Week 0 (baseline), Week 12 (pre-treatment), Week 13-24 (10-12 treatment sessions), Week 24 (post-treatment), Week 36 (follow-up)
|
Subjective rating of distress (SUDS)
|
UP-A: Week 0 (pre-treatment), Week 1-12 (10-12 treatment sessions), Week 12 (post-treatment), Week 24 (follow-up); TAU: Week 0 (baseline), Week 12 (pre-treatment), Week 13-24 (10-12 treatment sessions), Week 24 (post-treatment), Week 36 (follow-up)
|
|
Change of parental-reported problem severity throughout the treatment, from baseline to treatment completion and at the three-month follow-up
Time Frame: UP-A: Week 0 (pre-treatment), Week 1-12 (4-6 parent sessions), Week 12 (post-treatment), Week 24 (follow-up); TAU: Week 0 (baseline), Week 12 (pre-treatment), Week 13-24 (4-6 parent sessions), Week 24 (post-treatment), Week 36 (follow-up)
|
Subjective rating of distress - parents (SUDS - parents)
|
UP-A: Week 0 (pre-treatment), Week 1-12 (4-6 parent sessions), Week 12 (post-treatment), Week 24 (follow-up); TAU: Week 0 (baseline), Week 12 (pre-treatment), Week 13-24 (4-6 parent sessions), Week 24 (post-treatment), Week 36 (follow-up)
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Self-reported subjective satisfaction towards treatment
Time Frame: UP-A: Week 12 (post-treatment); TAU: Week 24 (post-treatment)
|
Satisfaction survey
|
UP-A: Week 12 (post-treatment); TAU: Week 24 (post-treatment)
|
|
Parental-reported subjective satisfaction towards treatment
Time Frame: UP-A: Week 12 (post-treatment); TAU: Week 24 (post-treatment)
|
Satisfaction survey (parents)
|
UP-A: Week 12 (post-treatment); TAU: Week 24 (post-treatment)
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Sophie Yan Yan Cheung, MSocSc, Chinese University of Hong Kong
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- UPAHK01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depressive Disorder
-
Aalborg University HospitalRecruitingDepressive Disorder | Depression | Depressive Episode | Depressive Disorders | Depressive Episodes | Depression - Major Depressive Disorder | Depressive Disorder, Major Depressive DisorderDenmark
-
Sheba Medical CenterNot yet recruiting
-
ACADIA Pharmaceuticals Inc.RecruitingACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response (NORLIGHT)Depressive Disorder, Treatment-Resistant | Major Depressive Disorder (MDD)United States
-
Rotman Research Institute at BaycrestRecruitingMajor Depressive Disorder (MDD)Canada
-
Hospital Universitari Vall d'Hebron Research InstituteRecruitingDepression - Major Depressive Disorder | Depression Chronic | Treatment-Resistant Major Depressive Disorder | Depression DisorderSpain
-
Second Affiliated Hospital of Tsinghua UniversityNot yet recruiting
-
First People's Hospital of HangzhouNot yet recruitingMajor Depressive Disorder
-
University of Wisconsin, MadisonNational Institute of Mental Health (NIMH)Recruiting
-
Shandong Provincial HospitalShandong UniversityRecruiting
-
Engrail Therapeutics INCCompletedMajor Depressive DisorderUnited Kingdom
Clinical Trials on Unified protocol for adolescents (UP-A)
-
University of MiamiCompletedDepression | Obsessive-Compulsive Disorder | Anxiety Disorders | Emotional Disorder | Adolescent - Emotional ProblemUnited States
-
University of MiamiNational Institute of Mental Health (NIMH)CompletedDepression | Anxiety DisordersUnited States
-
University of MiamiNational Institute of Mental Health (NIMH); University of ConnecticutCompletedDepression | AnxietyUnited States
-
Jian-Jun OuNot yet recruitingNon-suicidal Self-injury (NSSI)China
-
University of MiamiThe Children's Trust, Miami FLRecruitingDepressive Disorder | Parenting | Anxiety Disorder | Mental Health IssueUnited States
-
Anthony VescoNorthwestern University Feinberg School of Medicine; Substance Abuse and Mental...Not yet recruitingPosttraumatic Stress Disorders | Trauma | Posttraumatic Stress Symptoms | Chronic Medical Conditions | Chronic Medical Illness | Trauma Exposure | Chronic Medical Condition | Posttraumatic Stress | Posttraumatic Stress Disorder PTSD | Mental Health Functioning | Trauma and Stressor Related DisorderUnited States
-
Rotherham Doncaster and South Humber NHS Foundation...University of Sheffield; Innovate UK; MindLife UK LtdRecruitingAnxiety | Common Mental Health Problems | Depression DisordersUnited Kingdom
-
Boston University Charles River CampusUniversity of Kentucky; Harvard School of Public Health (HSPH)CompletedDepressive Disorder | Anxiety DisordersUnited States
-
Jian-Jun OuRecruitingNon-suicidal Self-injury (NSSI)China
-
University of Colorado, DenverChildren's Hospital Colorado; American Psychological FoundationCompletedEmotional DisorderUnited States